Moderna (MRNA) Inventory Average (2021 - 2026)
Moderna (MRNA) posted quarterly Inventory Average of $213.0 million for Q2 2026, up 15.76% year-over-year from $184.0 million in Q2 2025, and up 42.47% on a QoQ basis from $149.5 million in Q1 2026.
Moderna (MRNA) Inventory Average (2021 - 2026) Analysis & Trends
Moderna has reported Inventory Average for 6 years, with the latest figure at $213.0 million in Q2 2026.
- Inventory Average for Q2 2026 came in at $213.0 million, up 15.76% year-over-year; the trailing twelve-month figure through Jun 2026 was $213.0 million (up 15.76% YoY), and the FY2025 annual result was $135.0 million, down 15.36% from the prior year.
- Inventory Average advanced to $213.0 million in Q2 2026, from $149.5 million in the prior quarter.
- Over five years, Inventory Average peaked at $2.0 billion in Q3 2022 and troughed at $122.5 million in Q1 2025.
- A 5-year average of $672.6 million and a median of $345.8 million in 2023 frame the typical range for Inventory Average.
- The widest annual swing landed in 2022, when Inventory Average jumped 525.32%; it then tumbled 77.23% in 2023.
- A 5-year view of Inventory Average shows it stood at $1.5 billion in 2022, then tumbled by 77.23% to $344.5 million in 2023, then retreated by 23.22% to $264.5 million in 2024, then decreased by 8.32% to $242.5 million in 2025, then retreated by 12.16% to $213.0 million in 2026.
- Per Business Quant data, the three most recent Inventory Average figures were $213.0 million in Q2 2026, $149.5 million in Q1 2026, and $242.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.09 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 213.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 707.10 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 90.57 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 137.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 196.36 Mn |
| 10 | Roivant Sciences | 26.52 Bn | 26.52 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 213.00 Mn |
| Mar 31, 2026 | 149.50 Mn |
| Dec 31, 2025 | 242.50 Mn |
| Sep 30, 2025 | 286.00 Mn |
| Jun 30, 2025 | 184.00 Mn |
| Mar 31, 2025 | 122.50 Mn |
| Dec 31, 2024 | 264.50 Mn |
| Sep 30, 2024 | 405.50 Mn |
| Jun 30, 2024 | 347.00 Mn |
| Mar 31, 2024 | 248.50 Mn |
| Dec 31, 2023 | 344.50 Mn |
| Sep 30, 2023 | 601.00 Mn |
| Jun 30, 2023 | 723.50 Mn |
| Mar 31, 2023 | 840.50 Mn |
| Dec 31, 2022 | 1.51 Bn |
| Sep 30, 2022 | 2.00 Bn |
| Jun 30, 2022 | 1.93 Bn |
| Mar 31, 2022 | 1.69 Bn |
| Dec 31, 2021 | 1.20 Bn |
| Sep 30, 2021 | 804.00 Mn |